MML Investors Services
LUCD icon

MML Investors Services’s Lucid Diagnostics LUCD Stock Holding History

MML Investors Services’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.5K Hold
50,000
– – ﹤0.01% 3220
2026
Q1 		$57.5K Hold
50,000
– – ﹤0.01% 2930
2025
Q4 		$54.5K Hold
50,000
– – ﹤0.01% 2972
2025
Q3 		$50.5K Hold
50,000
– – ﹤0.01% 2863
2025
Q2 		$58K Buy
+50,000
New +$64.6K ﹤0.01% 2782

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

MML Investors Services's LUCD Position: Q2 2026 in Review

MML Investors Services held its Lucid Diagnostics (LUCD) position steady in Q2 2026 at 50,000 shares worth $53.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3220.

MML Investors Services first reported a position in LUCD in Q2 2025 and has held it in 5 quarters since. The position peaked at $58K in Q2 2025. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • MML Investors Services held 50,000 shares of Lucid Diagnostics worth $53.5K as of Q2 2026.
  • MML Investors Services left its Lucid Diagnostics share count unchanged in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #3220 holding.
  • MML Investors Services first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • MML Investors Services's Lucid Diagnostics position peaked at $58K in Q2 2025.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.